We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2018

Published: August 2018
Pages: 54
Code: 7A741ED898132A980FC578BCCD202A78
Format: PDF
Publisher Global Markets Direct
From Add to basket
$ 2,000.00
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide , provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.
Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide , provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 8 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Additonal Information

  • - The pipeline guide provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
  • - The pipeline guide reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • - The pipeline guide reviews key companies involved in Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • - The pipeline guide evaluates Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • - The pipeline guide reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease)

Companies Mentioned

3-V Biosciences Inc
Atriva Therapeutics GmbH
Autoimmune Technologies LLC
Biotron Ltd
CEL-SCI Corp
Fab’entech SA
GeneCure LLC
Gilead Sciences Inc
Novavax Inc
Oncovir Inc
Phelix Therapeutics LLC
Sanofi

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline depth and focus of Indication therapeutics. Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.
Add to basket
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Severe Acute Respiratory Syndrome (SARS) - Overview
  • Severe Acute Respiratory Syndrome (SARS) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development
  • 3-V Biosciences Inc
  • Atriva Therapeutics GmbH
  • Autoimmune Technologies LLC
  • Biotron Ltd
  • CEL-SCI Corp
  • Fab’entech SA
  • GeneCure LLC
  • Gilead Sciences Inc
  • Novavax Inc
  • Oncovir Inc
  • Phelix Therapeutics LLC
  • Sanofi
  • Severe Acute Respiratory Syndrome (SARS) - Drug Profiles
  • ATR-006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CEL-1000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CSW-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • D-3252 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs to Inhibit Cathepsin L for Coronaviridae Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FDX-000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LB-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ML-188 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibodies for Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody for SARS Virus Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Poly-ICLC - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • remdesivir - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SARS (virus like particle) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • severe acute respiratory syndrome vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit Coronavirus E Protein for Severe Acute Respiratory Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SSYA-10001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TVB-3567 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine for Severe Acute Respiratory Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Severe Acute Respiratory Syndrome (SARS) - Dormant Projects
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
  • List of Tables
  • Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by 3-V Biosciences Inc, H2 2018
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Atriva Therapeutics GmbH, H2 2018
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Autoimmune Technologies LLC, H2 2018
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Biotron Ltd, H2 2018
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by CEL-SCI Corp, H2 2018
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Fab’entech SA, H2 2018
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by GeneCure LLC, H2 2018
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Gilead Sciences Inc, H2 2018
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Novavax Inc, H2 2018
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Oncovir Inc, H2 2018
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Phelix Therapeutics LLC, H2 2018
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Sanofi, H2 2018
  • Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H2 2018
  • Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H2 2018 (Contd..1), H2 2018
  • List of Figures
  • Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Top 10 Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018

Keywords
;